


PRECISION MEDICINE & BIOMARKERS LEADERS SUMMIT: USA

BOSTON, USA
May 7-8 2018



Platinum Sponsor

intomics®

Other Exhibitors & Sponsors



#GEPMB18

www.global-engage.com



Examining groundbreaking biomarker, companion diagnostic, immuno-oncology, genomic, big data and AI research to facilitate the development of impactful personalized treatments for patients.

Global Engage is proud to host the **Precision Medicine & Biomarkers Leaders Summit USA** taking place on May 7-8, 2018 in Boston, MA, USA. The meeting is the sister event to the European Summit now in its fifth year.

The Summit will provide a forum to network, learn and engage with senior representatives of leading pharmaceutical and biotech companies worldwide who are there to further their research in Personalized medicine and enable impactful treatments for patients.

Tracks focus on R&D strategies, Biomarker development, Immuno-oncology, CDx development, AI and Big data analysis and approaches – Attending this Summit will provide you with the opportunity to mix and interact with experts working in all facets of Precision Medicine through the individual, panel and roundtable discussions on offer.

EXPERT SPEAKERS Include:



JAN LUNDBERG

President Lilly Research Labs (Head of R&D), Eli Lilly



BARBARA SOSNOWSKI

Vice President and ES&I Head, Cambridge Research Units; Global Head, WRD External Partnerships, Pfizer



ERIC PERAKSLIS

Senior Vice President, Informatics, Takeda



CARL BARRETT

Vice President, Translational Science, Oncology, AstraZeneca

DAY 1 – TRACK 1

Strategies and Technologies to Deliver Precision Medicine

- Current & future perspectives - Innovative initiatives, strategies and approaches
- Delivering superior outcomes for patients through personalized healthcare
- Technologies to enable Precision Medicine
 - AI for Precision medicine
 - Gene editing to deliver Precision Medicine
- Innovative clinical trial design
- Understanding physician, payer and patient perspectives
- Economics for precision medicine - Adding value
 - Incentivising pricing & reimbursement strategies
 - Market access considerations
- Ethical, regulatory & IP implications of individualizing medicine

DAY 1 – TRACK 2

Biomarkers in Clinical and Translational Development

- Patient selection strategies
 - Biomarkers for patient selection
- Clinical and translational biomarkers
 - Clinical biomarker discovery
 - Biomarker validation & qualification
 - Digital biomarkers

DAY 2 – TRACK 1

Companion Diagnostic Partnerships & Development

- CDx strategies and accelerating development
 - Evolution of companion diagnostics
 - Delivering a successful biomarker strategy alongside a companion diagnostic
- Lessons learnt and case studies from successful CDx collaborations & approvals
 - CDx development in Immuno-oncology
 - PDL1 Assays
- Rx-Dx partnerships, integration and co-development
- Overcoming regulatory issues; updates and future developments
- Reimbursement, market access & commercialization
- Complementary diagnostics

DAY 2 – TRACK 2

Immuno-Oncology

- Strategies
- Predictive biomarkers
- Immune checkpoint inhibitors
- Immune response monitoring
- Circulating Tumour DNA (ctDNA) - detection & monitoring - unlocking realtime information
 - Liquid biopsies – clinical utility

ROUNDTABLES

Roundtable 1: Harnessing AI to drive precision medicine

Roundtable 2: Conducting Precision medicine clinical trials

Roundtable 3: Advancing Liquid biopsy to the clinic

Roundtable 4: Developing “lean start up” commercialization strategies across clinical trials, strategic partners, and biomarker development

Roundtable 5: New Directions in Immuno-oncology

Roundtable 6: Cancer Prediction

PANEL DISCUSSIONS

Panel Discussion 1: Identifying the most promising directions for Precision research

Panel Discussion 2: Artificial Intelligence and machine learning – A paradigm shift in Pharma R&D

Panel Discussion 3: Precision Immuno-oncology - Where are we heading?

Panel Discussion 4: Biomarker Patient Selection Strategies

Panel Discussion 5: Companion Diagnostic regulation and reimbursement challenges

Panel Discussion 6: Overcoming CDx regulatory issues; updates / future developments and accelerating development

CONFIRMED SPEAKERS



ERIC PERAKSLIS
Senior Vice President,
Informatics, Takeda



BARBARA SOSNOWSKI
Vice President- External
Science & Innovation - Global
Head, Cambridge Research
Units and WRD External
Partnerships, Pfizer



THOMAS SKØT JENSEN
CEO, Intomics



CARL BARRETT
Vice President, Translational
Science, Oncology, AstraZeneca



MICHAEL SIERRA
Vice President, LEO Science &
Tech Hub



NIVEN NARAIN
President & CEO, Berg



ASIM SIDDIQUI
Chief Technology Officer,
NuMedii, Inc.



MICHAEL A. KIEBISH
Chief Precision Medicine
Officer, Berg



PALLAVI SACHDEV
Director, Oncology Biomarker
Research, Clinical Research,
Oncology Business Group, Eisai



HONEY V REDDI
Clinical Lab Director, Jackson
Laboratory for Genomic
Medicine



JAN LUNDBERG
President Lilly Research Labs
(Head of R&D), Eli Lilly



KOMAL SANE
Consultant, Genome
Interpretation and
Bioinformatics, Human
Longevity, Inc.



SABAH MALEK
Director, Global Regulatory
Strategy - Oncology, Eisai



RAN KAMIENCHICK
Senior Director, Diagnostic &
Personalized Medicine, Teva



NICOLE ST JEAN
Director, Precision Medicine,
Global Marketing, Oncology
Business Unit, AstraZeneca



WALID KAMOUN
Director, Head of
Nanotherapeutic & In Vivo
Pharmacology, Merrimack
Pharmaceuticals



LAURA KOONTZ
Personalized Medicine Staff,
Office of In Vitro Diagnostics
and Radiological Health, FDA



JEFFREY EVELHOCH
Vice President, Head of
Translational Biomarkers, Merck
Research Laboratories



**SENIOR
REPRESENTATIVE**
SeraCare



SCOTT D. PATTERSON
Vice President, Biomarker
Sciences, Gilead Sciences, Inc



JONATHAN PAN
Vice President, Head of
Translational Medicine and
Biomarker Strategy, Aevi
Genomic Medicine, Inc



AMIR HANDZEL
Co-founder and CEO, Pangea
Diagnostics



CECILIA SCHOTT
Vice President, Precision
Medicine, Global Product &
Portfolio Strategy, AstraZeneca



ROBERT PHILLIPS
Vice President & Head,
Precision Medicine, Pfizer



MICHAEL HOWELL
Senior Director of Translational
Research, Incyte Corporation



ROBERT SHORR
Co-Founder & Chief Scientific
Officer, Rafael Pharma



CAROLYN CUFF
Associate Director, Translational
Immunology,
Immunology Discovery, Abbvie



LISA ELI
Director, Translational Medicine
and Diagnostics, Puma
Biotechnology, Inc.



LASZLO RADVANYI
Senior Vice President; Head of
Immuno-Oncology Translational
Innovation Platform (TIP), EMD
Sero



STEFAN GLÜCK
Vice President, Global Medical
Affairs, Early Assets, Celgene



DEBRA CHAO
Associate Director, Oncology
Biologics, Discovery, Abbvie



PAMELA CARROLL
Senior Vice President, Immuno-
oncology, Genocoe Biosciences



SHENG FENG
Senior Principal Research
Statistician, Abbvie

CONFIRMED SPEAKERS



FRANCESCO GALIMI

Global Product General Manager, Early Development, Amgen, Inc.



JANUSZ DUTKOWSKI

Co-founder and CEO, Data4Cure



JEFF JUNE

CEO, Ischemia Care



STEFAN SCHERER

Vice President, Global Head Correlative Science, Novartis



DAVID SAHNER

Senior advisor to various companies in the Artificial Intelligence and Biotechnology sectors



SENIOR REPRESENTATIVE

Almac



ARIS BARAS

Vice President, Head, Regeneron Genetics Center - Regeneron Pharmaceuticals, Inc.



8:00-8:50

Registration & Refreshments

8:50-8:55

Global Engage Welcome Address and Morning Chair's Opening Remarks

9:00-9:35


**KEYNOTE ADDRESS:
ERIC PERAKSLIS**

Senior Vice President, Informatics, Takeda

Bringing it All Together, the Takeda Data Science Institute

- Data must flow smoothly throughout the entire biopharmaceutical product lifecycle
- Takeda has built a multi-disciplinary Data Institute that houses more than 165 data scientists from all disciplines
- Traditional data silos must fall and data ownership and access must be strategically aligned towards the most important questions in biopharma R&D

9:35-10:05


**KEYNOTE ADDRESS:
BARBARA SOSNOWSKI**

Vice President- External Science & Innovation – Global Head, Cambridge Research Units and WRD External Partnerships, Pfizer

Strategies to deliver precision medicine for drug discovery

- Precision Medicine: the value proposition in clinical development
- Understanding disease heterogeneity & drug response
- Human genetics complements biological rationale to identify robust targets

10:05-10:35


**SPONSORED PRESENTATION:
THOMAS SKØT JENSEN**

CEO, Intomics

Precision Medicine in a Data-rich Era – Challenges and Successful Bioinformatics Approaches

Biomedical data is generated in almost every stage of drug discovery and development and holds great promise as a powerful tool for enabling precision medicine.

- There are, however, a number of challenges that need to be overcome to make effective use of big data in R&D processes. One area of focus is establishing reliable hypotheses that can be tested with relatively small patient numbers in clinical trials given an incomplete biological understanding of the underlying disease.
- Using real world biomarker cases from non-oncology projects as a basis, the talk will present typical challenges and successful multi-omics approaches for identifying response biomarkers that correctly identify 85-95 % of the responding patients.

intomics

10:35-11:45

Morning Refreshments / Poster Presentations / One-to-One Meetings

STRATEGIES & TECHNOLOGIES TO DELIVER PRECISION MEDICINE

11:45-12:15


CARL BARRETT

Vice President, Translational Science, Oncology, AstraZeneca

Utility and challenges of ctDNA

- Plasma based assay using ctDNA can be used for patient selection, monitoring clinical responses and discovering mechanism of resistance to targeted therapies
- The development of an FDA approved EGFR ctDNA will be discussed
- Not all ctDNA assay provide the same results and the basis for this discordance will be provided

12:15-12:45

SPONSORED PRESENTATION

For sponsorship opportunities contact Tony Couch at
Email: tony@globalengage.co.uk
Tel: +1 6468 447 390 (USA)

12:45-1:35

**50 MINUTE EXECUTIVE PANEL DISCUSSIONS:
Identifying the most promising directions and
preparing for the future of Precision medicine
research**

MICHAEL SIERRA

Vice President, LEO Science & Tech Hub

BIOMARKERS IN CLINICAL AND TRANSLATIONAL DEVELOPMENT

11:45-12:15


JEFFREY EVELHOCH

Vice President, Head of Translational Biomarkers, Merck Research Laboratories

Biomarkers in Immuno-Oncology and Alzheimer's Disease

In the development of novel therapeutics, biomarkers can provide information critical to internal decision-making, identifying patients most likely to benefit from a specific treatment, establishing efficacy and/or safety for regulatory approval and generating new hypotheses for testing in additional preclinical or clinical studies. This talk will give several examples of how biomarkers are impacting clinical and translational development in immuno-oncology and Alzheimer's disease.

12:15-12:45


**SPONSORED PRESENTATION:
SENIOR REPRESENTATIVE**

SeraCare
Title TBC

12:45-1:35

**50 MINUTE EXECUTIVE PANEL DISCUSSIONS:
Biomarker Patient Selection Strategies**

SCOTT D. PATTERSON (Chair)

Vice President, Biomarker Sciences, Gilead Sciences, Inc

Senior Representatives x4

12:45-1:35

**PALLAVI SACHDEV**

Director, Oncology Biomarker Research, Clinical Research Oncology Business Group, Eisai

**JONATHAN PAN**

Vice President, Head of Translational Medicine and Biomarker Strategy, Aevi Genomic Medicine, Inc

**AMIR HANDZEL**

Co-founder and CEO, Pangea Diagnostics

**ROBERT PHILLIPS** (Reserved)

VP & Head, Precision Medicine, Pfizer

12:45-1:35

1:35-2:35

Lunch / One-to-One Meetings

2:35-3:05

**MICHAEL SIERRA**

Vice President, LEO Science & Tech Hub

Making Precision Medicine in Dermatology a Reality

- Defining precision medicine in dermatology
- Developing new technologies for data acquisition
- Building a platform that goes across indications
- Addressing the challenges of going from data to better patient care

2:35-3:05

**CECILIA SCHOTT**

Vice President, Precision Medicine. Global Product & Portfolio Strategy, AstraZeneca
Title TBC

3:05-3:20

**SPONSORED PRESENTATION:****JANUSZ DUTKOWSKI**

Co-founder and CEO, Data4Cure

The Biomedical Intelligence Cloud: Integrating Systems Biology and AI to continuously grow biomedical knowledge

- The CURIE Knowledge Graph as a dynamic knowledge base integrating information across millions of computational analysis on
- public and proprietary data
- Building data-driven maps of disease
- Deep molecular and immune-infiltrate disease characterization and subtyping
- Predicting and understanding pathways leading to response and resistance to single-agent therapies and drug combinations



3:20-3:35

SPONSORED PRESENTATION

For sponsorship opportunities contact Tony Couch at
Email: tony@globalengage.co.uk
Tel: **+1 6468 447 390 (USA)**

3:05-3:35

SPONSORED PRESENTATION

For sponsorship opportunities contact Tony Couch at
Email: tony@globalengage.co.uk
Tel: **+1 6468 447 390 (USA)**

50 MINUTE EXECUTIVE PANEL DISCUSSIONS:

**Artificial Intelligence and machine learning –
A paradigm shift in Pharma R&D****NIVEN NARAIN** (Chair)
President & CEO, Berg**ASIM SIDDIQUI**
Chief Technology Officer, NuMedii, Inc.**DAVID SAHRNER**
Senior advisor to various companies in the Artificial Intelligence and Biotechnology sectors**SHENG FENG**
Senior Principal Research Statistician, Abbvie**ROBERT PHILLIPS**Vice President & Head, Precision Medicine, Pfizer
Title TBC**MICHAEL HOWELL**

Senior Director of Translational Research, Incyte Corporation

**Precision Medicine Approaches in
Inflammatory Skin Diseases**

- Use of Omics approaches to understand disease heterogeneity and pathogenesis
- Integration of precision medicine approaches in clinical trials
- Define innovative approaches to predictive medicine


3:35-4:25

3:35-4:00

4:00-4:25

4:25-5:15

Afternoon Refreshments / Poster Presentations / One-to-One Meetings

**SENIOR REPRESENTATIVE** (Reserved)
Eisai AiM Institute, Eisai Inc.
Title TBC

5:15-5:45

**LISA ELI**

Director, Translational Medicine and Diagnostics, Puma Biotechnology, Inc.

**Neratinib for treatment of HER2-mutant
breast cancer**

- Somatic mutations in the ERBB2 (HER2) gene are a new class of oncogenic driver mutations detected in approximately 2% of breast cancer.
- ERBB2 mutations have been demonstrated to result in constitutive kinase signaling and increased tumor cell proliferation and growth in preclinical models.
- Neratinib, an irreversible pan-HER inhibitor, has been shown to have potent anti-tumor activity in HER2-amplified or ERBB2-mutated breast tumor cell lines and xenografts.
- Encouraging clinical activity of neratinib has been observed in patients with HER2-negative, ERBB2-mutation-positive metastatic breast cancers.
- The association of specific mutation patterns and response to neratinib is under analysis.

5:15-5:45

ONE HOUR ROUNDTABLE DISCUSSIONS:

**Table 1: Harnessing AI to drive precision
medicine****MICHAEL A. KIEBISH**
Chief Precision Medicine Officer, Berg**Table 2: Conducting Precision medicine
clinical trials****PALLAVI SACHDEV**
Director, Oncology Biomarker Research, Clinical Research, Oncology Business Group, Eisai**Table 3: Advancing Liquid biopsy to
the clinic****HONEY V REDDI**
Clinical Lab Director, Jackson Laboratory for Genomic Medicine

5:45-6:45

**CAROLYN CUFF**

Associate Director, Translational Immunology, Immunology Discovery, Abbvie

**Frontiers in Immunology: Targeting therapies
to the right patients**

- Autoimmune diseases are recognized as having significant heterogeneity that complicates the development of novel therapies as well as the ability to target approved therapies to the right patients.
- Pathway biomarkers can play a vital role in dose setting in clinical trials as well as identifying patients who are most likely to respond to specific treatments.
- A case study on the CD40 pathway in both pre-clinical and patient tissue will be presented to highlight the strategies that can be used to identify patients who might benefit from blockade of this pathway.

5:45-6:15



Table 4: Developing “lean start up” commercialization strategies across clinical trials, strategic partners, and biomarker development

JEFF JUNE

CEO, Ischemia Care



Table 5: New Directions in Immunology

STEFAN SCHERER

Vice President, Global Head Correlative Science, Novartis



Table 6: Cancer Prediction

THOMAS BOCK

CEO, HeritX

Table 7: Future of Precision Medicine

Table 8: Successful Companion Diagnostic partnership and co-development

Table 9: Rare diseases

Table 10: Patient selection biomarkers

Table 11: Another proposal of your choice



ROBERT SHORR

Co-Founder & Chief Scientific Officer, Rafael Pharma

Role of Infiltrating Circulating Tumor Cells in Screening of Anticancer Compounds and Formulations: CPI 613 a Cancer Metabolism Targeting Drug

- CPI 613, in phase 3 clinical trials for pancreatic cancer and AML, is a cancer mitochondrial metabolism disruptor.
- Tolerability and anticancer activity has been reported in single agent and drug combination studies.
- Circulating tumor cells of various types are reported in the literature as important features of metastasis
- Technology for the enrichment of invasive cancer cell populations capable of forming tumors in animal models has been reported.
- The availability of cells that may be responsible for metastasis for testing may contribute to the identification of more effective drugs.
- We report use of isolation methods for invasive circulating tumor cells and testing of CPI 613 activity against such cells derived from prostate, pancreatic, and other cancer patients.

5:45-6:45

6:15-6:45

6:45

Chair's Closing Remarks / End of Day 1

6:45-7:45

Drinks Reception

8:00-8:40

One-to-One Meetings & Refreshments

8:40-9:20


**KEYNOTE ADDRESS:
JAN LUNDBERG**

President Lilly Research Labs (Head of R&D), Eli Lilly

Precision Medicine and Biomarkers Technologies: Directions Across Different Therapeutic Areas

The talk will cover the following aspects, including lessons learned with examples from the Eli Lilly perspective:

- Biomarker technologies for patient selection with emphasis on oncology and Alzheimer's disease
- Evolution of companion diagnostics internally and through external collaborations
- Overcoming regulatory issues and market access

9:20-10:00


**KEYNOTE ADDRESS:
ARIS BARAS**

Vice President, Head, Regeneron Genetics Center - Regeneron Pharmaceuticals, Inc.

Title TBC

COMPANION DIAGNOSTIC PARTNERSHIPS & DEVELOPMENT

SPONSORED PRESENTATION

For sponsorship opportunities contact Tony Couch at

Email: tony@globalengage.co.uk

Tel: +1 6468 447 390 (USA)

10:00-10:30

IMMUNO-ONCOLOGY & LIQUID BIOPSIES

SPONSORED PRESENTATION

For sponsorship opportunities contact Tony Couch at

Email: tony@globalengage.co.uk

Tel: +1 6468 447 390 (USA)

10:00-10:30

10:30-11:40

Morning Refreshments / Poster Presentations / One-to-One Meetings

11:40-12:10

**LAURA KOONTZ**

Personalized Medicine Staff, Office of In Vitro Diagnostics and Radiological Health, FDA

Recent Initiatives in Precision Medicine

12:10-12:40

SPONSORED PRESENTATION

For sponsorship opportunities contact Tony Couch at

Email: tony@globalengage.co.uk

Tel: +1 6468 447 390 (USA)

45 MINUTE EXECUTIVE PANEL DISCUSSION:
Companion Diagnostic regulation and reimbursement challenges - Accelerating development
**KOMAL SANE (Chair)**

Consultant, Genome Interpretation and Bioinformatics, Human Longevity, Inc.

**SABAH MALEK**

Director, Global Regulatory Strategy - Oncology, Eisai

**SENIOR REPRESENTATIVE**

Almac Diagnostics

**JACQUELINE WRIGHT (Reserved)**

Director, Billing & Reimbursement, Boston Heart Diagnostics

Senior Representatives x2

12:40-13:20

11:40-12:10

**LASZLO RADVANYI**

Senior Vice President; Head of Immuno-Oncology Translational Innovation Platform (TIP), EMD Serono

Title TBC

12:10-12:40

SPONSORED PRESENTATION

For sponsorship opportunities contact Tony Couch at

Email: tony@globalengage.co.uk

Tel: +1 6468 447 390 (USA)

45 MINUTE EXECUTIVE PANEL DISCUSSION:
Precision Immuno-oncology where are we heading?
**STEFAN GLÜCK (Chair)**

Vice President, Global Medical Affairs, Early Assets, Celgene

**DEBRA CHAO**

Associate Director, Oncology Biologics, Discovery, Abbvie

**LASZLO RADVANYI (Reserved)**

Senior Vice President; Head of Immuno-Oncology Translational Innovation Platform (TIP), EMD Serono

Senior Representatives x2

12:40-13:20

12:20-1:35

15 MINUTE SOLUTION PROVIDER PRESENTATION

For sponsorship opportunities contact Tony Couch at
Email: tony@globalengage.co.uk
Tel: +1 6468 447 390 (USA)

12:20-1:35

15 MINUTE SOLUTION PROVIDER PRESENTATION

For sponsorship opportunities contact Tony Couch at
Email: tony@globalengage.co.uk
Tel: +1 6468 447 390 (USA)

1:35-2:30

Lunch / One-to-One Meetings

2:30-3:00

**RAN KAMIENCHICK**

Senior Director, Diagnostic & Personalized Medicine, Teva

Beyond CDx, beyond oncology; how biological and digital markers are redefining personalized medicine

- Can we connect the molecular, the physiological, and behavioral makeup of the patient to improve outcomes? (yes we can!!)
- What happens when the patient leaves the clinic? Moving from Snapshot to Continuous medicine
- How digital markers can augment current CDx approaches

2:30-3:00

**FRANCESCO GALIMI**

Global Product General Manager, Early Development, Amgen, Inc.

Title TBC

50 MINUTE EXECUTIVE PANEL DISCUSSION:

Developing successful Rx-Dx partnerships, integration and co-development

**NICOLE ST JEAN (Chair)**

Director, Precision Medicine, Global Marketing, Oncology Business Unit, AstraZeneca

Senior Representatives x5

3:00-3:50

3:00-3:25

**PAMELA CARROLL**

Senior Vice President, Immuno-oncology, Genoea Biosciences

Comprehensive discovery of tumor antigens for better personalized vaccines

- Personalized cancer vaccines are designed to activate tumor-specific neoantigen-activating T cells.
- The looming problem in the field are good technologies that can identify potent neoantigens from a patient's mutanome.
- The ATLAS technology detects bona fide antigens, without predictions, by rapidly screening a patient's peripheral blood T cells with their tumor-specific mutations presented by autologous dendritic cells.
- ATLAS-identified antigens have limited overlap with those identified by in silico methods.
- Neoantigens that induce either CD4+ or CD8+ T cell responses (or both) are identified.

3:25-3:50

**HONEY V REDDI**

Clinical Laboratory Director, Jackson Laboratory for Genomic Medicine

Liquid Biopsies in the clinic: Development and validation of a Pan Cancer panel

Liquid biopsies are currently being used by oncologists to monitor the effectiveness of treatment, in terms of resistance to therapies, to monitor disease recurrence, detect metastasis, and measure minimal residual disease. The JAX Liquid Biopsy test is a plasma based test evaluating 14 genes across 84 hotspots. The development and validation of this panel will be discussed.

3:50-4:20

**WALID KAMOUN**

Director, Head of Nanotherapeutic & In Vivo Pharmacology, Merrimack Pharmaceuticals

Translating preclinical mechanistic data to enable patient selection: Case studies for a Her-3-targeted monoclonal antibody and an EphA2-targeted antibody-directed nanotherapeutic

- Mechanism of action of MM-310, an EphA2-targeted antibody-directed nanotherapeutic, and biomarker translation approach
- Development of a first in class Her-3-targeted monoclonal antibody and biomarker hypothesis testing in the clinic

**STEFAN SCHERER**

Vice President, Global Head Correlative Science, Novartis

Liquid Biopsies - Title to be Confirmed

4:20

Conference Close

MAKING A POSTER PRESENTATION

Poster presentation sessions will take place in breaks and alongside the other breakout sessions of the conference. Your presentation will be displayed in a dedicated area, with the other accepted posters from industry and academic presenters. We also issue a poster eBook to all attendees with your full abstract in and can share your poster as a PDF after the meeting if you desire (optional). Whether looking for funding, employment opportunities or simply wanting to share your work with a like-minded and focused group, these are an excellent way to join the heart of this congress.

In order to present a poster at the congress you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). We charge an admin fee of €100 to industry delegates to present, that goes towards the shared cost of providing the poster presentation area and display boards, guides etc. This fee is waived for those representing academic institutions and not for profit organisations.





Boston Park Plaza,
50 Park Plaza, Arlington Street,
Boston, MA 02116-3912

Boston Park Plaza is so much more than a hotel. We are a Boston icon that is as much a part of the city's heritage as the Boston Tea Party and the annual Head of the Charles Regatta. We offer an experience that is truly one-of-a-kind, a place where you can enjoy a richly textured and profoundly memorable taste of the real Boston.

Following a landmark renovation, our hotel, Boston Park Plaza offers guests all the charisma and deeply individual charm of a historic hotel

with the effortless comforts of a new one. Once again a destination unto itself, our hotel offers incomparable proximity to everything that makes Boston a treasured destination. We are one of the most sought-after hotels near Boston Common and enjoy an ideal location among the hotels in downtown Boston, just steps away from the Public Garden, Theater District and many of the city's most popular historical sites.

When you're looking for the best hotel, Boston Park Plaza provides an unrivaled legacy of service. When Boston Park Plaza opened in 1927, it redefined a standard of hospitality that guests came to expect. With our history of innovation and continued dedication to our guests, we are proud to be recognized as Boston's Most Beloved.





DON'T DELAY, BOOK YOUR PLACE TODAY!

Places are limited and are based on a first come, first served basis so to avoid disappointment contact us today to reserve your place at Global Engage's Precision Medicine & Biomarkers Leaders Summit: USA on May 7-8 2018.

PHONE BOOKING

+1 648 447 390 (USA)

Our conference team will make all the necessary arrangements.

ONLINE BOOKING

Visit the website to book your place

www.global-engage.com/event/precision-medicine-usa

THE CONGRESS PACKAGE INCLUDES:

- All Conference Sessions
- Lunches and Refreshments
- Access to Exhibition Room
- Networking Drinks Reception
- Conference Workbook
- E-Document Pack

HOTEL ACCOMMODATION

Hotel accommodation will be available at a group rate.

FREE NEWSLETTER

For updates on the Precision Medicine & Biomarkers Leaders Summit: USA, plus free resources and reports, as and when our speakers authorise their release dates, check for updates at:

www.global-engage.com/event/precision-medicine-usa

SPONSORSHIP AND EXHIBITION OPPORTUNITIES AVAILABLE

For more details contact Tony Couch at

tony@globalengage.co.uk or call **+1 6468 447 390 (USA)**

T: +1 6468 447 390 (USA)
E: info@globalengage.co.uk
www.global-engage.com